Key Highlights
- ImmuPharma PLC (LSE:IMM) shares gained 4.43% on 6 October 2026.
- The company's primary goal is securing a value-enhancing licensing deal for its P140 autoimmune platform in 2026.
- Kapiglucagon, its type 1 diabetes candidate, is advancing through IND-enabling work with Bachem, Thermo Fisher and Kymos.
- A £6 million fundraise in 2026 extended the cash runway to at least the second half of 2028.
- A P140 international Patent filing update and a new peer-reviewed publication were released on 15 September 2026.
Why ImmuPharma (LSE:IMM) Shares Are Rising
ImmuPharma PLC (LSE:IMM) rose 4.43% on 6 October 2026, as investors continued to position for a potential partnering deal for its lead P140 programme. The specialist drug discovery and development company has repeatedly said that securing a P140 licensing agreement is its primary objective for 2026, and with the final quarter of the year now under way, anticipation is building.
Speculative biotech stocks such as ImmuPharma often move ahead of expected catalysts, and the shares have shown in the past how sharply they can react to partnering news, including jumps of 20% to 25% on P140 updates earlier in the year.
P140: The Lead Asset
P140 is ImmuPharma's autoimmune technology platform, a peptide-based therapy that works by modulating autophagy, a cellular process implicated in autoimmune diseases. The company has been in active discussions with potential partners and in March 2026 released a P140 programme update that sent the shares sharply higher. On 15 September 2026 ImmuPharma provided a P140 international patent filing update and announced a new peer-reviewed publication, both strengthening the scientific and commercial case. Research in Murcia has also flagged P140 as a potential brain cancer treatment.
The chairman has said a licensing deal could be negotiated from a position of strength thanks to the company's improved financial position.
Kapiglucagon: Second Key Asset
ImmuPharma's second key programme is Kapiglucagon, a treatment for severe hypoglycaemia in people with type 1 diabetes. In May 2026 the company initiated an IND-enabling programme for Kapiglucagon. It has since built a network of partners: Bachem to manufacture the active pharmaceutical ingredient (June 2026); Thermo Fisher as contract development and Manufacturing organisation (July 2026); and Kymos as bioanalytical contract research partner (August 2026). These steps move the programme toward clinical trials.
Funding Strengthened
In March 2026 ImmuPharma announced a fundraise including a £6 million subscription with Lanstead and a £468,000 retail offer, approved by shareholders in April. The company says this extends its cash runway to at least the second half of 2028, giving it flexibility to accelerate Kapiglucagon and selectively invest in earlier-stage programmes. Final results for 2025 showed reduced losses, and the half-year report published on 15 September 2026 updated investors on progress.
At the 2026 AGM in June, all resolutions passed with strong support of 93% to 99%, including authority to allot shares and new articles of association.
Why Investors Are Watching LSE:IMM
- Partnering catalyst: A P140 licensing deal could provide upfront payments and validation.
- Diabetes opportunity: Kapiglucagon targets an important unmet need in type 1 diabetes.
- Funded runway: Cash expected to last into the second half of 2028.
- Patent progress: Strengthened intellectual property supports deal value.
- Wider network: ImmuPharma has links to fellow AIM company Incanthera, which has drawn attention in 2026.
Risks to Consider
Drug development carries high risk of failure, and there is no guarantee a P140 partnering deal will be concluded. The Lanstead subscription structure can affect share price dynamics. Further dilution is possible, and the shares are highly speculative and volatile.
Outlook
News on P140 partnering discussions remains the single most important catalyst for LSE:IMM. Investors will also watch for Kapiglucagon progress toward the clinic and any additional research publications.






Please wait processing your request...